Electronic transmission disclaimer

IMPORTANT: You must read the following before continuing. This electronic transmission applies to the attached presentation slides (the “Document”) and you are therefore advised to read this carefully before reading, accessing or making any other use of the attached Document. In accessing this electronic transmission and the attached Document, you agree to be bound by the following terms and conditions, and the terms and conditions set out in the slide headed “Disclaimer”, including any modifications made to them from time to time, each time you receive any information as a result of such access. If you are not the intended recipient of this transmission, please do not distribute, disseminate or copy the information contained in this electronic transmission and the attached Document, but instead delete and destroy all copies of this electronic transmission and the attached Document.

The attached Document is being furnished to you solely for your information and does not constitute an offer of securities to persons to whom it is directed or contain investment advice to you and you are not authorised to, and you may not forward or deliver the attached Document, electronically or otherwise, to any person or reproduce the attached Document in any manner whatsoever. Any forwarding, distribution or reproduction of the attached Document in whole or in part is unauthorised. If you have gained access to this transmission contrary to any of the foregoing restrictions, you are not authorised and will not be able to purchase any of the securities described in the attached Document.

The attached Document has been sent to you or accessed by you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and, consequently, none of the Company, Shore Capital and Corporate Limited, Shore Capital Stockbrokers Limited or Stifel Nicolaus Europe Limited (together, the “Brokers”) or their respective affiliates, directors, officers, employees, representatives and agents or any other person controlling such persons accepts any liability or responsibility whatsoever, in respect of any difference between the document distributed to you in electronic format and the hard copy version. Please ensure that your copy of the attached Document is complete. The company, the Brokers and each of their respective affiliates accordingly disclaims all and any liability whether arising in tort, contract or otherwise which they might otherwise have in respect of such electronic transmission, the attached Document or any such statement. No representation or warranty, express or implied, is made by the Company, the Brokers or any of their respective affiliates as to the accuracy, completeness or sufficiency of the information set out in this electronic transmission or the attached Document. By accessing the attached Document, you consent to receiving it in electronic form.

If you receive the attached Document by electronic transmission, you should not reply to this electronic transmission. Any reply to electronic transmissions, including those you generate by using the “Reply” function on your electronic transmission software, will be ignored or rejected. You are responsible for protecting yourself against viruses and other destructive items. Your receipt of the attached Document by electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

You acknowledge that this electronic transmission and the delivery of the attached Document and its contents are confidential and intended only for you and you will not transmit the attached Document (or any copy of it or part thereof) or disclose, whether orally or in writing, any of its contents to any other person.
Disclaimer

This presentation has been prepared by Amryt Pharma plc (the "Company"). By receiving this presentation and/or attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.

This presentation is intended to be delivered in (a) member states of the European Economic Area to persons who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive (as defined below); and (b) in the United Kingdom, to (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) (the "Order"); (ii) high net worth bodies corporate, unincorporated associations, partnerships and trustees of high value trusts as described in Article 49(2)(a)-(d) of the Order; or (iii) persons to whom it would otherwise be lawful to distribute it (all such persons being "Relevant Persons"). Any person who is not a Relevant Person may not view the presentation and should not act or rely on the presentation or any of its contents. Any investment or investment activity to which the presentation relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. If you have received this presentation and you are not a Relevant Person, you must return it immediately to the Company. The term "Prospectus Directive" used in this paragraph refers to Directive 2003/71/EC (as amended) and includes any relevant implementing regulations in each member state of the European Economic Area.

This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the "Group") or in any other entity, nor shall this document or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment decision, nor does it constitute a recommendation regarding the securities of the Group. Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Group’s securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel.

Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in the United States, Canada, Australia, Japan or any other jurisdiction which prohibits or restricts the same except in compliance with applicable securities laws. Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. No responsibility is accepted, and to the fullest extent permitted by law or regulation, no representation, undertaking, warranty or other assurance is made or given, in either case, expressly or impliedly, by the Group or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors ("Affiliates") or any other person, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same. Accordingly, no such person will be liable for any indirect, consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the presentation.

The information contained in this presentation has not been independently verified. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor in securities of the Group may desire or require in deciding whether or not to offer to purchase such securities. The information in this presentation includes forward-looking statements, made in good faith, which are based on the Group’s or, as appropriate, the Group’s directors’ current expectations and projections about future events. These forward-looking statements may be identified by the use of forward-looking terminology including, but not limited to, the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussion of the Group’s strategy, plans, operations, financial performance and condition, objectives, goals, future events or intentions. These forward-looking statements, as well as those included in any other material discussed at any analyst presentation, are subject to risks, uncertainties and assumptions about the Group and investments many of which are outside of the Group’s control, including, among other things, the development of its business, the trends in its operating industry, changing economic, financial, or other market conditions and future capital expenditures. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may differ materially from those indicated in these statements. Forward-looking statements may, and often do, materially differ from actual results. Thus, these forward-looking statements should be treated with caution and the recipients of the presentation should not rely unduly on any forward-looking statements. None of the future projections, expectations, estimates or prospects or any other statements contained in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation.

The information and opinions contained in this presentation and any other material discussed verbally are provided as at the date of this presentation and are subject to verification, completion and change without notice. The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the AIM Rules for Companies published by the London Stock Exchange plc and the Market Abuse Regulation (Regulation 596/2014) (each as amended from time to time), neither the Group nor any of its Affiliates, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation neither the Group nor any of its Affiliates, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent.

Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice.
Presenting Team

Dr Joe Wiley – CEO
▲ 20+ years in healthcare and private equity
▲ Opened and led Sofinnova Ventures European office
▲ Previously Medical Director at Astellas Pharma

“...We have assembled commercial & development expertise over the last 3 years to drive sustained pipeline growth...” Dr. Joe Wiley

Dr Mark Sumeray – CMO
▲ 17 years’ experience in the pharmaceutical, medical devices and biotech sectors
▲ Chief Medical Officer at Aegerion Pharmaceuticals
▲ Previously VP Cardiovascular Metabolics US Medical at Bristol-Myers Squibb

Rory Nealon – COO/CFO
▲ CFO/COO of Trinity Biotech
▲ Oversaw the acquisition and integration of 12 companies in 5 countries
▲ Previously CFO of Conduit plc, an Irish telecoms company
▲ Previously associate director within structured finance team in AIB

David Allmond – CCO
▲ 20 years’ experience in the pharmaceutical industry in commercial roles
▲ President EMEA at Aegerion Pharmaceuticals
▲ Previously Corporate Vice President of Global Marketing for Celgene Corporation

Team & infrastructure to scale our business for future growth
Amryt Overview

**Revenue generating** orphan drug company targeting rare diseases with high unmet medical need

**Proven commercial** infrastructure built across EMEA

**Lead commercial asset** - Lojuxta €11.9m of revenue in 2017

With a strong **pipeline of development assets**

Including **Phase III (AP 101)** which represents a >€1.0bn potential market opportunity*

Growing existing assets and exploring in-license opportunities

*Management Estimates

**Building a world leader in rare & orphan diseases**
Significant high unmet medical need opportunities globally

- **7,000** rare diseases identified
- **50%** of those affected are children and **30%** of these children won’t see their **5th birthday**
- Rare disease patients comprise **6-8%** of the EU population
- **22%** of worldwide prescriptions by **2024**
- **$262bn** by **2024**
- Growth of **11%** per annum vs. **6.4%** for overall Pharma market
- **350m** rare disease patients globally
- **30m** Americans suffer from a rare disease

Sources: (1) National Organisation for Rare Diseases; (2) European Organisation for Rare Diseases; (3) Genetic Alliance UK; (4) European Union Committee of Experts on Rare Diseases; (5) Global Genes Allies in Rare Diseases; and (6) Evaluate Pharma Orphan Drug Report 2018
Momentum Building - Accelerated & Disciplined Growth

2015
- Amryt formed
- 1st two acquisitions agreed

2016
- Episalvan (AP101) approved by EMA
- IPO on AIM
- €20m EIB debt facility agreed
- Lojuxta in-licensed

2017
- Largest Global EB Phase III study (EASE) started
- €15m equity fund raise

2018
- Lojuxta-territorial growth & expansion
- AP101 – EASE protocol refined & enhanced
- Interim efficacy analysis expected Q4 2018
- AP103 Gene therapy platform in-licensed

2019 +
- AP101 (EASE) – Top-line data expected Q2 2019
- Grow existing assets
- Acquire new assets
- In-license opportunities
- Support development pipeline

Building a track record of successful execution
Commercial & Development Pipeline

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lojuxta ▼ (lomitapide)¹</td>
<td>Adult HoFH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Episalvan (Oleogel S10)²</td>
<td>Partial Thickness Wounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>AP101 (Oleogel S10)</td>
<td>Epidermolysis Bullosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lojuxta ▼ (lomitapide)¹</td>
<td>Familial Chylomicronaemia Syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP103 (Gene Therapy)</td>
<td>Epidermolysis Bullosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. The European Commission (EC) granted authorisation to lomitapide under the trade name Lojuxta® ▼ in July 2013.

Pipeline focused on diseases with a high unmet medical need
Vision & Strategy

To build a world leader in rare & orphan diseases by acquiring, developing & commercialising products that help improve the lives of patients where there is a high unmet medical need.

- Acquire, develop & commercialise medicines to improve the lives of patients with rare & orphan diseases
- Track record of buying & managing assets well
- Well connected – excellent access to deal flow
- Compelling value proposition for payers
- Unique skillset in European reimbursement regime
- Lojuxta
- AP101
- AP102
- AP103
- In-license opportunities

Building a world leader in rare & orphan diseases
H1 2018 Highlights

▲ Revenue growth of 13.6% driven by excellent performance from Lojuxta

▲ Significant expansion of Lojuxta territories to include Russia & CIS

▲ 8 new Lojuxta distribution agreements signed - 22 countries now covered

▲ AP101 - EASE study progressing well - largest ever Global Phase III study in EB

▲ Exciting new gene therapy platform - AP103 - acquired in March 2018

▲ €12.2m in Cash with €10.0m undrawn balance on EIB facility* at 30/06/18
  *€5m of this undrawn balance was subsequently drawn down in September 2018

Post Period-End Events & Outlook

▲ AP101 IND approval from the FDA - permits the opening of US clinical trial sites

▲ FDA grant of Paediatric Rare Disease designation for AP101

▲ EASE – last patient required for unblinded interim efficacy analysis to be enrolled by end Sept

▲ AP103 - pre-clinical efficacy data expected in Q4

▲ Significant momentum built in Lojuxta through H1 continues in H2:
  ▲ First orders received from UK & Saudi Arabia
  ▲ Recent NHS reimbursement approval
  ▲ Growth in new distributor markets

Building a world leader in rare & orphan diseases
## 3 Pillars of Growth

### NEAR-TERM COMMERCIALISATION

<table>
<thead>
<tr>
<th>LOJUXTA</th>
<th>IN-LICENSE OPPORTUNITIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ Total license territory opportunity estimated at &gt;€125m*</td>
<td>▲ Add more commercial assets</td>
</tr>
<tr>
<td>▲ Sales in 2017 of €11.9m</td>
<td>▲ Leverage the commercial, medical &amp; regulatory infrastructure in place</td>
</tr>
<tr>
<td>▲ Right people in place</td>
<td>▲ Grow presence in rare &amp; orphan disease space</td>
</tr>
<tr>
<td>▲ Reimbursement events – potential for ‘stepwise revenue growth’</td>
<td></td>
</tr>
<tr>
<td>▲ Drive revenue growth in existing &amp; new territories</td>
<td></td>
</tr>
</tbody>
</table>

### EB PIPELINE

- **AP101**
  - EASE Global Phase III study
  - Interim read out Q4 2018
  - Top line Q2 2019
  - New life-cycle opportunities

- **AP103**
  - Novel non-viral gene therapy for EB

---

“....A truly commercial company...with a sales, medical and regulatory infrastructure in place...primed & ready to acquire, develop & commercialise more assets...” Dr. Joe Wiley

---

*Management Estimates*
3 Pillars of Growth

Lojuxta
Positive momentum building for lead commercial asset
Lojuxta - Lead Commercial Asset

▲ Prescription medicine, in-licensed by Amryt (Dec 16), approved in Europe to treat adults with HoFH

  • Market exclusivity in EEA, Russia & CIS, Middle East & North Africa

▲ Untreated mean life expectancy is 18 years, extending to mean 45-48 years with current standard of care but still a substantial deficit

▲ Lojuxta:

  • Reduces LDL-C in adult HoFH patients
  • Appropriate treatment population represents 40-50% of HoFH patients *
  • 2017 Sales of €11.9m

▲ Positive momentum in negotiations on national reimbursement levels

▲ Increases in individual ‘named patients’ being treated

▲ Future growth from both existing & new territories

* Management Estimate

What is HoFH?
HoFH is a life threatening disorder that impairs the body’s ability to remove LDL ‘bad’ cholesterol from the blood. Typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature blocking of arterial blood vessels manifesting as cardiovascular disease.
Lojuxta - LDL Apheresis is current Standard of Care for HoFH

Before

After

With permission Prof Dan Rader, Pennsylvania University, US
Lojuxta - Italian Real World Data Demonstrates Significant Efficacy

- The addition of Lojuxta at the average dosage of 19 mg/day lowered LDL-C levels at the nadir by $76.5 \pm 16.7\%$.
- At their last visit, 60% of patients showed LDL-C<100 mg/dL and 47% <70 mg/dL (more stringent target with cardiovascular disease).

Source: D’Erasmo et al, “Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real World Clinical Experience in Italy” 2017
Lojuxta - Rapidly Establishing Commercial Footprint & Infrastructure

...to capture a total HoFH market opportunity of approx. €125m*...

<table>
<thead>
<tr>
<th>Country</th>
<th>Population (M)</th>
<th>Estimated HoFH Pop.</th>
<th>Eligible Pop.</th>
<th>Market Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU 5**</td>
<td>321</td>
<td>482</td>
<td>241</td>
<td>€ 38,520,000</td>
</tr>
<tr>
<td>EU 23</td>
<td>180</td>
<td>270</td>
<td>135</td>
<td>€ 21,600,000</td>
</tr>
<tr>
<td>Russia / CIS / Balkans ****</td>
<td>307</td>
<td>460</td>
<td>230</td>
<td>€ 23,000,000</td>
</tr>
<tr>
<td>GCC</td>
<td>50</td>
<td>150</td>
<td>75</td>
<td>€ 12,000,000</td>
</tr>
<tr>
<td>Other ***</td>
<td>200</td>
<td>600</td>
<td>300</td>
<td>€ 30,000,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,058</td>
<td>1,962</td>
<td>981</td>
<td>€ 125,120,000</td>
</tr>
</tbody>
</table>

* Management Estimates (as of 2017)
** UK, Germany, Spain, Italy, France
*** Turkey, Algeria, Iran
**** Territory expansion agreement executed in May 2018

Commercial infrastructure primed & ready for more assets
Pathway to Reimbursement

1. Strong clinical submission around the unmet need and the efficacy/safety of the product

2. Clinician/prescriber alignment on the need for Lojuxta and positioning in the clinical pathway

3. Passionate patient group support communicating that patients are waiting for access

4. Strong value proposition (including cost effectiveness data provided informally)

5. Effective government affairs strategy & action plan

6. Media activity on the disease and unmet medical need

7. Confidential commercial deal to meet payer expectations

REIMBURSEMENT
3 Pillars of Growth

In-Licensing
Identifying future commercial opportunities
In-License Opportunities

Focus on rare & orphan diseases

Excellent visibility on sector deal flow globally

High unmet medical need

Replicating success of Lojuxta

Significant commercial opportunity

Leveraging existing commercial, medical & regulatory infrastructure

Late-stage (peri-launch) or commercial assets

Track record of buying & managing assets well
3 Pillars of Growth

Our pipeline

Building a franchise in Epidermolysis Bullosa (EB)
Comparison of Healing Process between PTWs and EB Wounds

Wound healing is a 4-stage process\textsuperscript{1,2}

1. **Haemostasis**
   Fluid damming

2. **Controlled inflammatory response**
   Macrophage-mediated, cytokine-modulated endothelial cell expansion, keratinocyte activation

3. **Granulation/proliferation**
   Collagen formation and fibroblast activity, keratinocyte migration

4. **Remodelling/maturation**
   Contraction of the wound to full tensile strength

Wounds in EB resemble Partial Thickness Wounds

\textsuperscript{1} Mercandetti, Wound Healing and Repair, Medscape 2017

\textsuperscript{2} Eming SA, et al. Sci Transl Med 2014;6:265sr6

EB - AP101 – Lead Development Asset

- Approved in the EU, Norway and Iceland for the treatment of Partial Thickness Wounds (PTWs) in adults

- Being developed as a prescription medicine for EB - also a PTW

- Promotes the differentiation & migration of skin cells to accelerate wound healing

- Largest ever Global Phase III (EASE) patient study for EB currently underway

What is EB? – Epidermolysis Bullosa (EB) is a rare genetic skin disorder that leads to extremely fragile skin, and children with the disorder are often referred to as ‘butterfly children’. There are currently no approved treatments for EB.

Amryt Proof of Concept Study in EB

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>Representative photo series</th>
<th>Primary efficacy endpoint</th>
</tr>
</thead>
</table>
| AP101 + Wound dressing | | \[Which half epithelialized faster?\]
| Wound dressing alone | | [8] [0] [4] (p < 0.01) |

Amryt

- Approved in the EU, Norway and Iceland for the treatment of Partial Thickness Wounds (PTWs) in adults
- Being developed as a prescription medicine for EB - also a PTW
- Promotes the differentiation & migration of skin cells to accelerate wound healing
- Largest ever Global Phase III (EASE) patient study for EB currently underway

Strong progress achieved in advancing AP101
Double blind, randomised, placebo controlled, Phase III, Efficacy and Safety Study of AP101 in 192 Patients with inherited Epidermolysis Bullosa*; unblinded interim efficacy analysis after 96 patients

Visit schedule
- Day0
- D14
- D30
- D45
- D60
- D90
- Month 0
- M3
- M12
- M24

AP101 + dressing
Placebo + dressing

90 day main study phase
2 year open label extension

Primary Endpoint: proportion of target wounds healed by day 45*

*Excludes EB Simplex

Unblinded interim efficacy analysis expected Q4 2018
Read out of top-line data expected Q2 2019

Significant milestone with interim efficacy analysis due Q4
AP101 - Short & Mid-Term Value Creating Clinical Milestones

**Indication**
- EB (AP101)

**2017**
- Phase III EB (192 pat.)
- FPFV

**2018**
- Interim Efficacy Analysis
- USA IND

**2019**
- Breakthrough Designation
- Topline Data
- CTD
- MAA
- EMA approval

**2020**
- CTD
- NDA
- FDA approval
- Ad Comm

**Non-clinical studies**

**Follow-up Study**

**Non-human studies**

**Patient studies**

Two significant value generating milestones pending in EB
AP101 – Single Asset, Multiple Indications Under Evaluation

Approved by the EMA in the EU, Norway & Iceland for treatment of PTW in adults (Jan 2016)

Evaluating life-cycle opportunities for AP101

Dermatological conditions include:

- Severe burns
- Toxics Epidermal Necrolysis Syndrome (TENS)/Stevens-Johnson Syndrome (SJS)
- Bullous Pemphigoid
- Pemphigus Vulgaris
- Grade III/IV radiotherapy and chemotherapy induced dermatitis

Positive interest from physicians to study AP101 in these indications

New indications represent significant additional opportunities
AP103 – Building an EB Franchise - Gene Therapy Platform

▲ Novel non-viral gene therapy for EB
▲ Mar 2018 – completed in-licensing of new platform technology
▲ Involves delivery of gene therapy using HPAE polymer technology
▲ Benefits:
  • Simple & novel topical application
  • Strong efficacy seen in pre-clinical models
  • Potential immunogenicity benefit vs viral vector products
  • Non-integrating – regular/ongoing application
  • Potentially easier to manufacture than viral vector products
▲ Initial focus on Recessive Dystrophic EB (RDEB) with potential efficacy for other indications
▲ Pre-clinical trials currently underway – early results expected Q4 2018

Exclusively licensed HPAE Polymer Technology for use as a novel gene delivery platform in EB which if successful, could eliminate the requirement for viruses as delivery vectors – and could provide a substantial competitive advantage to Amryt.

Progressing our exciting pipeline of development assets
**AP103 – Gene Therapy**

**Collagen VII Expression** - with a single topical application and increased post three topical applications

**Uptake Pathway of the Polyplexes**

*Demonstrated efficacy in pre-clinical EB model*
# Financials (unaudited)

<table>
<thead>
<tr>
<th></th>
<th>H1 2018 €m</th>
<th>H1 2017 €m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>7.02</td>
<td>6.18</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>4.31</td>
<td>3.67</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>4.24</td>
<td>5.36</td>
</tr>
<tr>
<td>LPS</td>
<td>4.14c</td>
<td>6.64c</td>
</tr>
<tr>
<td>Cash</td>
<td>12.21</td>
<td>10.94</td>
</tr>
</tbody>
</table>

- Lojuxta revenue driven by strong demand in existing and new licensed territories
- Positive momentum in reimbursement discussions across Amryt territories
- R&D spend primarily related to the advancement of AP101 clinical studies
- Debt – LT facility for €20m agreed with EIB (Dec 2016) of which €10m drawn at 30 June 2018 *

*€5m of this undrawn balance was subsequently drawn down in September 2018

“….prudent cost & cash management supports pipeline development to key milestones ...”

Dr. Joe Wiley

*Flexibility to grow, enhance & develop our portfolio of assets
Investment Case

- Compelling global market opportunity in rare & orphan diseases
- Revenue generating orphan drug company
- Exciting portfolio of commercial & development stage assets
- Strong management team with over 170 years industry experience
- Significant & scalable commercial, regulatory & medical infrastructure in place
- Excellent access to deal flow globally

Building a world leader in rare & orphan diseases
### Analyst Coverage

<table>
<thead>
<tr>
<th>Analyst</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shore Capital</td>
<td><a href="mailto:adam.barker@shorecap.co.uk">adam.barker@shorecap.co.uk</a></td>
<td>0151 600 3707</td>
</tr>
<tr>
<td>Stifel Nicolaus</td>
<td><a href="mailto:max.herrmann@stifel.com">max.herrmann@stifel.com</a></td>
<td>+44 207 710 7606</td>
</tr>
<tr>
<td>Davy</td>
<td><a href="mailto:andrew.young@davy.ie">andrew.young@davy.ie</a></td>
<td>+353 1 614 9192</td>
</tr>
</tbody>
</table>

### Significant Shareholders

<table>
<thead>
<tr>
<th>Significant Shareholders</th>
<th>Holding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software AG - Stiftung</td>
<td>22.30%</td>
</tr>
<tr>
<td>AXA Framlington</td>
<td>9.80%</td>
</tr>
<tr>
<td>Raglan Capital</td>
<td>8.99%</td>
</tr>
<tr>
<td>Dr Joe Wiley (CEO)</td>
<td>7.64%</td>
</tr>
<tr>
<td>Legal &amp; General</td>
<td>5.19%</td>
</tr>
<tr>
<td>Amati</td>
<td>4.80%</td>
</tr>
<tr>
<td>Rory Nealon (CFO)</td>
<td>3.52%</td>
</tr>
<tr>
<td>Alan Harris</td>
<td>3.23%</td>
</tr>
</tbody>
</table>

### Contact

<table>
<thead>
<tr>
<th>Contact</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Joe Wiley</td>
<td><a href="mailto:joe.wiley@amrytpharma.com">joe.wiley@amrytpharma.com</a></td>
</tr>
<tr>
<td>Rory Nealon</td>
<td><a href="mailto:rory.nealon@amrytpharma.com">rory.nealon@amrytpharma.com</a></td>
</tr>
<tr>
<td>Dr Mark Sumeray</td>
<td><a href="mailto:mark.sumeray@amrytpharma.com">mark.sumeray@amrytpharma.com</a></td>
</tr>
<tr>
<td>David Allmond</td>
<td><a href="mailto:david.allmond@amrytpharma.com">david.allmond@amrytpharma.com</a></td>
</tr>
<tr>
<td>Investor Relations</td>
<td><a href="mailto:ir@amrytpharma.com">ir@amrytpharma.com</a></td>
</tr>
</tbody>
</table>

### Financial Calendar

<table>
<thead>
<tr>
<th>Financial Calendar</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interim Results</td>
<td>Sep 2018</td>
</tr>
<tr>
<td>FY 2018</td>
<td>Mar 2019</td>
</tr>
</tbody>
</table>